🇺🇸 Azithromycin for Oral Suspension in United States

12 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Product Dispensing Error — 2 reports (16.67%)
  2. Rash — 2 reports (16.67%)
  3. Abdominal Discomfort — 1 report (8.33%)
  4. Abdominal Pain Upper — 1 report (8.33%)
  5. Abnormal Behaviour — 1 report (8.33%)
  6. Crying — 1 report (8.33%)
  7. Drug Ineffective — 1 report (8.33%)
  8. Eczema — 1 report (8.33%)
  9. Expired Product Administered — 1 report (8.33%)
  10. Feeling Abnormal — 1 report (8.33%)

Source database →

Azithromycin for Oral Suspension in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Azithromycin for Oral Suspension approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Azithromycin for Oral Suspension in United States?

University of California, San Francisco is the originator. The local marketing authorisation holder may differ — check the official source linked above.